{"entity":{"id":"nct07036250","kind":"trial","name":"Clinical Study of U32 in Patients With Acute Myeloid Leukemia","aka":[],"tldr":"A phase 1/2 trial of U32 CAR-T in acute myeloid leukaemia, run by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, now recruiting.","summary":"Clinical Study of U32 in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT07036250 by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, with 20 participants planned, started 2025-07-03 and due to reach its primary completion in 2027-12-31. Interventions recorded: U32 CAR-T.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07036250","url":"https://clinicaltrials.gov/study/NCT07036250"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":["unicar-therapy"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07036250","phase":"1/2","setting":"A Single-arm, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of U32 Injection in Patients With Acute Myeloid Leukemia.","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","started":"2025-07-03","startedType":"estimated","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07036250/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"company":[{"id":"unicar-therapy","kind":"company","name":"Unicar-Therapy","route":"/companies/unicar-therapy/"}]}}